Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay, great.

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : We'll talk more about that in a minute now, maybe just in terms of your partnership with Pfizer, and clearly, you have a pretty substantial collaboration going on. And I know Pfizer is very interested in the breast cancer space. Maybe just can you talk a little bit about that, how the partnership is going. Any potential for expansion? We know that Pfizer is looking at the next-generation CDK4 as well. Maybe just a comment on that. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 28, 2023 / 3:30PM, ARVN.OQ - Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay, great. So maybe let's talk about your ER degrader. I think that's clearly the focus for investors. And as you mentioned earlier, you're doing the Phase 3 second-line study. And the top line is going to come out next year, which is going to be a big moment for you. Maybe just walk us through the trial design. It looks like you're excluding patients treated with chemotherapy. Maybe just talk a little bit about what's the rationale behind that?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay, got it. Maybe just give us an update on the enrollment, how is it going so far?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : I see a thumbs up.

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. Ron, so I guess just to follow up on your comment earlier about ESR1 mutant versus not, obviously, you're enrolling both. But just from the data we've seen, it looks like the response may be a little bit different in mutant versus wild type. So maybe just talk a little bit about why you guys are confident that you may be able to go for the all-comers here?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. So you mentioned the control arm is fulvestrant, and we know this drug hasn't shown great results here, particularly in the CDK4/6 setting. So maybe just remind us what the benchmark here is. And you alluded to your Phase 2 data. Maybe just help us to put that into context. REFINITIV STREETEVENTS | www.refinitiv.com | Contact Us consent of Refinitiv. 'Refinitiv' and the Refinitiv logo are registered trademarks of Refinitiv and its affiliated companies. SEPTEMBER 28, 2023 / 3:30PM, ARVN.OQ - Arvinas Inc at Cantor Fitzgerald Global Healthcare Conference

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. So I wanted to talk a little bit about your front-line Phase 3 study you're combining with palbo here, so that's the VERITAC-3 study. And I know you added a lead-in portion to the study. Maybe just walk us through the trial design, timeline, and maybe just make some comment on the enrollment as well?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : In terms of data update later this year, would you be able to share a PFS data or it's too early?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : PFS.

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. In terms of safety, obviously, we're very focused on neutropenia. So what is the rate that you think you should be good for the combination?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Yes, right. So aside from palbo combo, you're also testing combination with other CDK4/6. Maybe just talk a little bit about your work there and what are your expectations? And when are we going to see data?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. Maybe just on the competitive landscape front, are we're looking at multiple players here in both front line and second line? Maybe just make some comment on your current thinking around your position relative to some pretty big funnel plays here.

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : That's fair. Now let's switch to your ER franchise. I know you're going to update data as well. Maybe just set the expectations for us.

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. So in terms to the Phase 3 study that you guys are going to initiate this year, how should we think about the trial design and the right comparator arm here?

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay, that's fair. Now talking about your next-generation AR degrader, 766, you shared some data this year. Maybe just give us some highlights in how are you going to position this compound relative to your --

Question: Li Watsek - Cantor Fitzgerald, L.P. - Analyst : Okay. So we spent a lot of time talking about oncology, but I know you guys are also doing a lot of work in neuro and CNS. So tell us a little bit about that, and what are you excited about?